Ask AI
ProCE Banner Events

Share

Myeloma Masterclass: Adopting the Latest Guidelines for Evidence-Based, Equitable Care

This 1.5-hour interactive satellite symposium held in conjunction with the 2026 ASCO Annual Meeting in Chicago, Illinois, will provide perspectives from experts who serve on the NCCN Multiple Myeloma (MM) Panel on the latest clinical developments and clinical guidance about recent data and emerging treatment advances in the personalization of care of patients with smoldering and symptomatic MM. 

Not an official event of the 2026 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.

Physicians ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits

Pharmacists: 1.50 contact hours (0.15 CEUs)

Nurse Practitioners/Nurses: 1.50 Nursing contact hours

Nurse Practitioners/Nurses: 1.25 hours of pharmacotherapy credit

Who Should Attend

This activity is intended for hematologists, oncologists, advanced practice providers, nurses, pharmacists, physician associates, and other healthcare professionals who care for patients with multiple myeloma. 

Time and location

Saturday, May 30, 2026

6:30 PM - 8:30 PM Central Time (CT)

In-person

7:00 PM - 8:30 PM Central Time (CT)

Virtual

Hilton Chicago
720 S Michigan Avenue
Chicago, Illinois 60625

TBD

Agenda

  • Overview and Unmet Needs and Disparities in MM
  • Evaluating and Managing Smoldering MM
  • Optimal Treatment of Newly Diagnosed MM
  • New Treatment Options for Previously Treated MM
  • Optimizing Therapy Sequencing in R/R MM
  • Key Questions and Controversies in MM Management
  • Up-to-Date Algorithm for MM Treatment
  • Audience Question and Answer Session

Location

Venue Name

Hilton Chicago

Address

Hilton Chicago
720 S Michigan Avenue
Chicago, Illinois 60625

Room Name

TBD

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge, confidence, and competence of learners in integrating new and emerging therapies into practice, thereby improving clinical outcomes for patients with multiple myeloma.

Target Audience
This activity is intended for hematologists, oncologists, advanced practice providers, nurses, pharmacists, physician associates, and other healthcare professionals who care for patients with multiple myeloma. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Initiate timely systemic treatment for appropriate patients based on risk assessment and the latest multiple myeloma diagnostic and staging criteria

  • Develop individualized treatment strategies for patients with newly diagnosed multiple myeloma through consideration of the available clinical data as well as NCCN Guidelines, risk assessment, comorbidities, and patient age/fitness and preferences

  • Select optimal sequencing and bridging therapies for patients with relapsed/refractory multiple myeloma based on individual patient and disease characteristics, as well as NCCN Guideline recommendations and response to and tolerance of previous therapies

  • Appraise the latest clinical data for current and emerging therapies/regimens for patients with multiple myeloma

  • Implement strategies to improve access, quality of care, and equitable clinical trial enrollment for all patients with multiple myeloma

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

NCCN designates this educational activity for a maximum of 1.5 contact hours. This program offers 1.25 pharmacotherapeutic contact hours for nurses. 

Continuing Pharmacy Education

NCCN designates this Application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-26-036-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregated participant data will be shared with the commercial supporters of this activity.

For ABIM MOC points, your information will be shared with the ABIM through NCCN’s Joint Accreditation Program and Activity Reporting System (JA-PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving NCCN permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

Disclosure of Conflicts of Interest
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships. In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. Full disclosure of faculty relationships will be made prior to the activity. 

Acknowledgement

Provided by

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Decera Clinical Education.

NCCN

Supporter

Supported by educational grants from AstraZeneca and Johnson & Johnson.
This educational activity is supported by an independent medical education grant from GSK.

AstraZeneca

GSK

Johnson & Johnson

Partner

Clinical Care Options, LLC dba Decera Clinical Education

Clinical Care Options, LLC dba Decera Clinical Education

Contact Information

For customer support please click here.

Mailing Address:

 

Decera Clinical Education
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191

 

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.